| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria | 9 | 2011 | 1239 | 0.970 |
Why?
|
| Plasmodium chabaudi | 7 | 2011 | 22 | 0.920 |
Why?
|
| Anemia | 7 | 2006 | 1502 | 0.660 |
Why?
|
| Erythropoiesis | 3 | 2006 | 706 | 0.580 |
Why?
|
| HSP70 Heat-Shock Proteins | 12 | 2013 | 403 | 0.550 |
Why?
|
| Hodgkin Disease | 11 | 2017 | 1415 | 0.540 |
Why?
|
| Erythropoietin | 7 | 2006 | 726 | 0.520 |
Why?
|
| Erythrocytes | 4 | 2006 | 2455 | 0.420 |
Why?
|
| Heat-Shock Proteins | 10 | 2011 | 820 | 0.390 |
Why?
|
| Reticulocytosis | 3 | 2006 | 10 | 0.380 |
Why?
|
| Hot Temperature | 16 | 2004 | 1351 | 0.380 |
Why?
|
| Fiducial Markers | 1 | 2012 | 136 | 0.370 |
Why?
|
| Radiation-Sensitizing Agents | 5 | 2005 | 358 | 0.330 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2012 | 356 | 0.320 |
Why?
|
| Interleukin-12 | 3 | 2006 | 577 | 0.280 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2006 | 708 | 0.260 |
Why?
|
| Radiosurgery | 2 | 2012 | 1331 | 0.250 |
Why?
|
| Interleukin-2 | 1 | 2011 | 1904 | 0.230 |
Why?
|
| Ribosomal Protein S6 Kinases | 3 | 2004 | 205 | 0.230 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 1613 | 0.230 |
Why?
|
| Antigens, Protozoan | 1 | 2006 | 322 | 0.230 |
Why?
|
| Erythroid Precursor Cells | 1 | 2004 | 218 | 0.220 |
Why?
|
| Radiation Oncology | 3 | 2007 | 555 | 0.220 |
Why?
|
| Spleen | 7 | 2011 | 2359 | 0.220 |
Why?
|
| Cell Division | 4 | 2007 | 4568 | 0.210 |
Why?
|
| Biological Assay | 3 | 2002 | 650 | 0.210 |
Why?
|
| Interferon-gamma | 2 | 2011 | 3205 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2011 | 3874 | 0.200 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 307 | 0.190 |
Why?
|
| Antibodies, Protozoan | 1 | 2002 | 253 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 4386 | 0.180 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 4 | 2000 | 494 | 0.180 |
Why?
|
| Gap Junctions | 2 | 2001 | 233 | 0.180 |
Why?
|
| Flow Cytometry | 3 | 2011 | 5973 | 0.180 |
Why?
|
| Antigen Presentation | 1 | 2006 | 1283 | 0.180 |
Why?
|
| Salicylic Acid | 1 | 1999 | 56 | 0.180 |
Why?
|
| NF-kappa B | 6 | 2010 | 2500 | 0.170 |
Why?
|
| Etanidazole | 2 | 1996 | 26 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 4 | 2014 | 1063 | 0.160 |
Why?
|
| Mice | 37 | 2018 | 81154 | 0.160 |
Why?
|
| Heat-Shock Response | 4 | 2011 | 163 | 0.160 |
Why?
|
| Transcription, Genetic | 10 | 2011 | 7719 | 0.160 |
Why?
|
| Chaperonins | 2 | 2008 | 62 | 0.160 |
Why?
|
| DNA-Binding Proteins | 14 | 2005 | 9648 | 0.150 |
Why?
|
| Injury Severity Score | 1 | 2001 | 1014 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 2988 | 0.150 |
Why?
|
| Antigens, Ly | 1 | 2018 | 290 | 0.150 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 137 | 0.150 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 1999 | 514 | 0.150 |
Why?
|
| Cytokines | 7 | 2010 | 7324 | 0.150 |
Why?
|
| Buthionine Sulfoximine | 1 | 1996 | 18 | 0.140 |
Why?
|
| Animals | 55 | 2018 | 168660 | 0.140 |
Why?
|
| Interleukin-10 | 3 | 2011 | 1200 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 10 | 2018 | 21824 | 0.140 |
Why?
|
| Type C Phospholipases | 2 | 1993 | 292 | 0.130 |
Why?
|
| Radiobiology | 1 | 1996 | 85 | 0.130 |
Why?
|
| Phospholipases A | 2 | 1993 | 216 | 0.130 |
Why?
|
| Cancer Vaccines | 2 | 2013 | 1023 | 0.120 |
Why?
|
| Cricetinae | 16 | 2009 | 2475 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2006 | 2720 | 0.120 |
Why?
|
| Kidney | 4 | 2005 | 7185 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 8430 | 0.120 |
Why?
|
| Neurofilament Proteins | 1 | 1996 | 318 | 0.120 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 2077 | 0.120 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 94 | 0.120 |
Why?
|
| Coculture Techniques | 3 | 2006 | 1342 | 0.120 |
Why?
|
| Calcium | 9 | 2009 | 5755 | 0.120 |
Why?
|
| Mice, Inbred A | 2 | 2004 | 248 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 2 | 2009 | 548 | 0.110 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 846 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 6620 | 0.100 |
Why?
|
| Molecular Chaperones | 4 | 2022 | 742 | 0.100 |
Why?
|
| Cricetulus | 11 | 2009 | 818 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 1422 | 0.100 |
Why?
|
| Cell Survival | 9 | 2007 | 5881 | 0.100 |
Why?
|
| Cells | 1 | 1993 | 167 | 0.100 |
Why?
|
| Monocytes | 5 | 2002 | 2593 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2002 | 103 | 0.100 |
Why?
|
| Caspase 12 | 1 | 2010 | 11 | 0.100 |
Why?
|
| HeLa Cells | 9 | 2011 | 3130 | 0.100 |
Why?
|
| Immobilization | 1 | 2012 | 236 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 3794 | 0.090 |
Why?
|
| Shock | 1 | 1993 | 318 | 0.090 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 341 | 0.090 |
Why?
|
| Leukotriene B4 | 2 | 2001 | 294 | 0.090 |
Why?
|
| Cell Line | 17 | 2007 | 15993 | 0.090 |
Why?
|
| Epithelial Cells | 3 | 2005 | 3690 | 0.090 |
Why?
|
| ADAM Proteins | 2 | 2009 | 243 | 0.090 |
Why?
|
| Hyperthermia, Induced | 3 | 2001 | 404 | 0.090 |
Why?
|
| Misonidazole | 2 | 1989 | 34 | 0.090 |
Why?
|
| Sugar Phosphates | 2 | 1987 | 43 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2009 | 1381 | 0.090 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 135 | 0.090 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 310 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 1637 | 0.090 |
Why?
|
| Neoplasms | 5 | 2014 | 21675 | 0.090 |
Why?
|
| Inositol Phosphates | 2 | 1987 | 180 | 0.090 |
Why?
|
| Calmodulin | 1 | 1990 | 209 | 0.090 |
Why?
|
| Fibroblasts | 7 | 2005 | 4162 | 0.080 |
Why?
|
| Arachidonic Acids | 1 | 1989 | 299 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 6363 | 0.080 |
Why?
|
| Interleukin-1 | 3 | 2002 | 1263 | 0.080 |
Why?
|
| Host-Parasite Interactions | 1 | 2011 | 294 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 793 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 8 | 2005 | 6311 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 2010 | 3701 | 0.080 |
Why?
|
| Prostaglandins | 1 | 1989 | 405 | 0.080 |
Why?
|
| 3T3 Cells | 4 | 1999 | 1102 | 0.080 |
Why?
|
| Nitroimidazoles | 1 | 1989 | 106 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2001 | 2401 | 0.080 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 844 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 9 | 2004 | 5867 | 0.080 |
Why?
|
| Mammary Glands, Animal | 2 | 2001 | 276 | 0.080 |
Why?
|
| Quality of Life | 2 | 2009 | 12788 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 806 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2016 | 2037 | 0.080 |
Why?
|
| Spinal Cord | 1 | 1996 | 1809 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2001 | 520 | 0.080 |
Why?
|
| Salivary Glands | 1 | 2009 | 229 | 0.080 |
Why?
|
| Aspirin | 1 | 1999 | 3283 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2010 | 1533 | 0.080 |
Why?
|
| Thiamphenicol | 1 | 2006 | 2 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 423 | 0.070 |
Why?
|
| Pheochromocytoma | 1 | 1989 | 337 | 0.070 |
Why?
|
| Transfection | 10 | 2007 | 5892 | 0.070 |
Why?
|
| Mycobacterium bovis | 1 | 2007 | 150 | 0.070 |
Why?
|
| Ovary | 5 | 1987 | 980 | 0.070 |
Why?
|
| Cell Cycle Proteins | 2 | 2008 | 3463 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2022 | 3750 | 0.070 |
Why?
|
| Aleutian Mink Disease | 1 | 2005 | 1 | 0.070 |
Why?
|
| Transcription Factors | 14 | 2011 | 12209 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 424 | 0.070 |
Why?
|
| Cerebral Angiography | 1 | 2012 | 1285 | 0.070 |
Why?
|
| Salmonella Infections | 1 | 2007 | 173 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2007 | 270 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2016 | 4026 | 0.070 |
Why?
|
| Receptors, Cell Surface | 3 | 2005 | 2865 | 0.070 |
Why?
|
| Phantoms, Imaging | 2 | 2012 | 2479 | 0.070 |
Why?
|
| Stress, Physiological | 2 | 2011 | 1403 | 0.070 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2007 | 180 | 0.060 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2005 | 57 | 0.060 |
Why?
|
| Virus Shedding | 1 | 2005 | 109 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 667 | 0.060 |
Why?
|
| Phosphorylation | 9 | 2004 | 8436 | 0.060 |
Why?
|
| Ferrets | 1 | 2005 | 194 | 0.060 |
Why?
|
| Male | 32 | 2020 | 349776 | 0.060 |
Why?
|
| Humans | 57 | 2022 | 743811 | 0.060 |
Why?
|
| Apoptosis | 5 | 2007 | 9718 | 0.060 |
Why?
|
| Quercetin | 2 | 2004 | 93 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2004 | 480 | 0.060 |
Why?
|
| Neuregulin-1 | 1 | 2005 | 142 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 6 | 2007 | 6380 | 0.060 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2005 | 163 | 0.060 |
Why?
|
| Prostatic Neoplasms | 5 | 2007 | 11059 | 0.060 |
Why?
|
| Interleukin-6 | 4 | 2002 | 3208 | 0.060 |
Why?
|
| Salmonella typhimurium | 2 | 2007 | 351 | 0.060 |
Why?
|
| Gallium Radioisotopes | 1 | 2005 | 178 | 0.060 |
Why?
|
| Signal Transduction | 8 | 2010 | 23398 | 0.060 |
Why?
|
| Genes, Reporter | 6 | 2007 | 1545 | 0.060 |
Why?
|
| Female | 36 | 2020 | 380020 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 19894 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4467 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2001 | 1284 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2009 | 1180 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2004 | 4422 | 0.060 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 16674 | 0.060 |
Why?
|
| 14-3-3 Proteins | 1 | 2004 | 214 | 0.060 |
Why?
|
| Neoplasm Staging | 8 | 2017 | 11036 | 0.060 |
Why?
|
| Survivors | 1 | 2014 | 2291 | 0.060 |
Why?
|
| Cell Membrane | 4 | 2007 | 3749 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2018 | 1728 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2009 | 2615 | 0.060 |
Why?
|
| Bleomycin | 3 | 2014 | 512 | 0.060 |
Why?
|
| Lipopolysaccharides | 5 | 2002 | 2217 | 0.060 |
Why?
|
| Untranslated Regions | 1 | 2022 | 31 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2005 | 486 | 0.050 |
Why?
|
| Vinblastine | 3 | 2014 | 501 | 0.050 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 1709 | 0.050 |
Why?
|
| Calcimycin | 3 | 2000 | 222 | 0.050 |
Why?
|
| Sphingosine | 1 | 2004 | 306 | 0.050 |
Why?
|
| Particle Accelerators | 1 | 2003 | 173 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2018 | 7880 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 396 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2004 | 296 | 0.050 |
Why?
|
| Pyruvate Kinase | 1 | 2004 | 189 | 0.050 |
Why?
|
| Oncogenes | 1 | 2008 | 1265 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 1222 | 0.050 |
Why?
|
| Salmonella Infections, Animal | 1 | 2002 | 65 | 0.050 |
Why?
|
| CHO Cells | 5 | 2009 | 1409 | 0.050 |
Why?
|
| Sulindac | 1 | 2001 | 29 | 0.050 |
Why?
|
| Carrier State | 1 | 2005 | 518 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2002 | 151 | 0.050 |
Why?
|
| DNA | 2 | 1999 | 7295 | 0.050 |
Why?
|
| Lymphoma, Follicular | 1 | 2005 | 435 | 0.050 |
Why?
|
| Immune Sera | 1 | 2002 | 641 | 0.050 |
Why?
|
| Concanavalin A | 1 | 1981 | 191 | 0.050 |
Why?
|
| Phospholipases A2 | 2 | 1993 | 203 | 0.050 |
Why?
|
| Protein Kinase C | 2 | 1998 | 1227 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 972 | 0.050 |
Why?
|
| Respiration | 1 | 2008 | 1653 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2004 | 613 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2000 | 2281 | 0.050 |
Why?
|
| Dacarbazine | 3 | 2014 | 566 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 1826 | 0.050 |
Why?
|
| Movement | 1 | 2008 | 1471 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2002 | 290 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 2282 | 0.050 |
Why?
|
| Career Choice | 1 | 2007 | 743 | 0.050 |
Why?
|
| Tritium | 1 | 2001 | 745 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 959 | 0.050 |
Why?
|
| Uridine | 1 | 2001 | 146 | 0.050 |
Why?
|
| Robotics | 1 | 2008 | 899 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2004 | 1147 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 193 | 0.050 |
Why?
|
| Breast | 1 | 2009 | 1970 | 0.050 |
Why?
|
| Procarbazine | 2 | 2014 | 181 | 0.050 |
Why?
|
| Mechlorethamine | 2 | 2014 | 136 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2006 | 1539 | 0.040 |
Why?
|
| Connexin 43 | 1 | 2001 | 207 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 11524 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2001 | 236 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 1962 | 0.040 |
Why?
|
| Species Specificity | 1 | 2004 | 2480 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 964 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 13691 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2001 | 371 | 0.040 |
Why?
|
| Mitogens | 1 | 1999 | 232 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2002 | 623 | 0.040 |
Why?
|
| Interphase | 1 | 1999 | 226 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 2000 | 225 | 0.040 |
Why?
|
| Rats | 5 | 2001 | 24250 | 0.040 |
Why?
|
| Teaching | 1 | 2007 | 1173 | 0.040 |
Why?
|
| Connexins | 1 | 2001 | 357 | 0.040 |
Why?
|
| Plasmids | 4 | 2007 | 2308 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2000 | 338 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2006 | 11478 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2005 | 1301 | 0.040 |
Why?
|
| Lung | 5 | 2009 | 9858 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2018 | 74 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2007 | 1181 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 9731 | 0.040 |
Why?
|
| Cell Movement | 2 | 2022 | 5216 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2002 | 608 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 2509 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 1903 | 0.040 |
Why?
|
| Gene Expression Regulation | 6 | 2011 | 12066 | 0.040 |
Why?
|
| G1 Phase | 1 | 1999 | 415 | 0.040 |
Why?
|
| Vincristine | 2 | 2014 | 1039 | 0.040 |
Why?
|
| Doxorubicin | 3 | 2014 | 2234 | 0.040 |
Why?
|
| Genes, fos | 1 | 1997 | 183 | 0.040 |
Why?
|
| Pneumonia | 1 | 2009 | 2133 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2010 | 2789 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11360 | 0.040 |
Why?
|
| Cells, Cultured | 7 | 2005 | 19232 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2011 | 13112 | 0.040 |
Why?
|
| DNA Damage | 2 | 2018 | 2429 | 0.040 |
Why?
|
| Mitochondria | 1 | 2009 | 3513 | 0.040 |
Why?
|
| Phosphatidylinositols | 2 | 1988 | 291 | 0.030 |
Why?
|
| DEAE-Dextran | 2 | 1986 | 10 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2011 | 676 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2002 | 2969 | 0.030 |
Why?
|
| Thymus Gland | 1 | 2001 | 1266 | 0.030 |
Why?
|
| DNA Repair | 2 | 1996 | 2045 | 0.030 |
Why?
|
| Dogs | 1 | 2001 | 3911 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1999 | 1802 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2007 | 2961 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2001 | 861 | 0.030 |
Why?
|
| Transcriptional Activation | 3 | 2009 | 1783 | 0.030 |
Why?
|
| Superoxides | 1 | 1996 | 387 | 0.030 |
Why?
|
| Middle Aged | 15 | 2017 | 213241 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2002 | 960 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2002 | 1212 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 5230 | 0.030 |
Why?
|
| Aged | 13 | 2017 | 163178 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 1620 | 0.030 |
Why?
|
| Prednisone | 2 | 2014 | 1574 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1997 | 575 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 5524 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 8939 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2007 | 1914 | 0.030 |
Why?
|
| Ethanol | 1 | 1981 | 1343 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2005 | 13028 | 0.030 |
Why?
|
| Serine | 1 | 1998 | 825 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2005 | 430 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2010 | 14563 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2009 | 876 | 0.030 |
Why?
|
| Neoplasm Transplantation | 3 | 2005 | 2085 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 3617 | 0.030 |
Why?
|
| Combined Modality Therapy | 5 | 2005 | 8637 | 0.030 |
Why?
|
| Time Factors | 10 | 2009 | 40038 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 3769 | 0.030 |
Why?
|
| Adult | 14 | 2017 | 213889 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1996 | 813 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 3 | 1993 | 114 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 9272 | 0.030 |
Why?
|
| Dextrans | 2 | 1986 | 595 | 0.030 |
Why?
|
| Recurrence | 4 | 2007 | 8337 | 0.030 |
Why?
|
| Adolescent | 9 | 2014 | 85729 | 0.030 |
Why?
|
| Aged, 80 and over | 8 | 2014 | 57744 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2000 | 1640 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1993 | 326 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2014 | 40964 | 0.030 |
Why?
|
| Protein Binding | 5 | 2004 | 9377 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2375 | 0.030 |
Why?
|
| Luciferases | 3 | 2000 | 733 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 4749 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 2131 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1994 | 821 | 0.030 |
Why?
|
| Macrophages | 1 | 2007 | 5651 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 513 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 1993 | 321 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 1994 | 271 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 2004 | 829 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1996 | 1794 | 0.030 |
Why?
|
| Cause of Death | 2 | 2017 | 3580 | 0.030 |
Why?
|
| Child | 8 | 2014 | 77637 | 0.030 |
Why?
|
| Sodium Salicylate | 2 | 2002 | 19 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2009 | 6895 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2005 | 3680 | 0.030 |
Why?
|
| Disease Progression | 3 | 2005 | 13273 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2007 | 567 | 0.020 |
Why?
|
| Protein Biosynthesis | 3 | 2004 | 2123 | 0.020 |
Why?
|
| Temperature | 3 | 2004 | 2202 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 13869 | 0.020 |
Why?
|
| Adenosine Triphosphate | 2 | 2009 | 2029 | 0.020 |
Why?
|
| Age of Onset | 2 | 2010 | 3268 | 0.020 |
Why?
|
| Glutathione Transferase | 2 | 2004 | 595 | 0.020 |
Why?
|
| Thrombin | 2 | 1993 | 598 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2004 | 5179 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 10629 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1996 | 2725 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1999 | 2440 | 0.020 |
Why?
|
| Blood | 1 | 1993 | 596 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20121 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 1994 | 730 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 18107 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 1691 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 4561 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2002 | 354 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 826 | 0.020 |
Why?
|
| Neurons | 1 | 1989 | 9336 | 0.020 |
Why?
|
| Amino Acid Substitution | 2 | 2007 | 1793 | 0.020 |
Why?
|
| Amifostine | 1 | 2009 | 41 | 0.020 |
Why?
|
| Bradykinin | 1 | 1989 | 214 | 0.020 |
Why?
|
| Salivary Glands, Minor | 1 | 2009 | 27 | 0.020 |
Why?
|
| Mediastinum | 1 | 2010 | 267 | 0.020 |
Why?
|
| Submandibular Gland | 1 | 2009 | 86 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2009 | 365 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1990 | 197 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 20827 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 2009 | 90 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1993 | 969 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 18027 | 0.020 |
Why?
|
| Xerostomia | 1 | 2009 | 95 | 0.020 |
Why?
|
| Intermediate Filaments | 1 | 1989 | 175 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2014 | 670 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 153 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2004 | 2086 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2006 | 1275 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1990 | 1157 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6539 | 0.020 |
Why?
|
| Toll-Like Receptors | 2 | 2002 | 593 | 0.020 |
Why?
|
| Parotid Gland | 1 | 2009 | 168 | 0.020 |
Why?
|
| Models, Biological | 3 | 2007 | 9582 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1994 | 2183 | 0.020 |
Why?
|
| beta-Galactosidase | 2 | 2000 | 574 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 7270 | 0.020 |
Why?
|
| Glycogen Synthase Kinases | 2 | 1998 | 40 | 0.020 |
Why?
|
| RNA, Catalytic | 1 | 2007 | 50 | 0.020 |
Why?
|
| Eicosanoids | 1 | 1989 | 279 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2007 | 55 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 355 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 4848 | 0.020 |
Why?
|
| Massachusetts | 2 | 2014 | 8660 | 0.020 |
Why?
|
| Receptors, Concanavalin A | 1 | 1986 | 11 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 3480 | 0.020 |
Why?
|
| Exhalation | 1 | 2008 | 167 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 2879 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 1986 | 80 | 0.020 |
Why?
|
| Research | 1 | 1996 | 1999 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 5185 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Parasitemia | 1 | 2007 | 173 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 14714 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 689 | 0.020 |
Why?
|
| Phosphatidic Acids | 1 | 1986 | 49 | 0.020 |
Why?
|
| Health Services Research | 1 | 2014 | 1836 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2007 | 5787 | 0.020 |
Why?
|
| Multigene Family | 1 | 1990 | 1101 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2008 | 292 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6356 | 0.020 |
Why?
|
| Down-Regulation | 1 | 1994 | 3000 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2017 | 77410 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 2891 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2001 | 1723 | 0.020 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2005 | 17 | 0.020 |
Why?
|
| Diglycerides | 1 | 1986 | 176 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2005 | 118 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5854 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 589 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 5691 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2011 | 1532 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2009 | 669 | 0.020 |
Why?
|
| Mathematics | 2 | 2003 | 727 | 0.020 |
Why?
|
| Sex Factors | 2 | 2014 | 10394 | 0.020 |
Why?
|
| Disease Susceptibility | 2 | 2002 | 1781 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2004 | 46 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 13809 | 0.020 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2004 | 39 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1376 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2007 | 434 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 769 | 0.020 |
Why?
|
| Methionine | 1 | 1987 | 590 | 0.020 |
Why?
|
| Endosomes | 1 | 2007 | 518 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1987 | 1800 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2007 | 327 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 809 | 0.020 |
Why?
|
| Research Design | 1 | 2020 | 5983 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2007 | 641 | 0.020 |
Why?
|
| Career Mobility | 1 | 2007 | 262 | 0.020 |
Why?
|
| Disintegrins | 1 | 2004 | 25 | 0.020 |
Why?
|
| Oligopeptides | 1 | 1990 | 1188 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2004 | 344 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 240 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1985 | 425 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 2692 | 0.020 |
Why?
|
| Gold | 1 | 2008 | 485 | 0.020 |
Why?
|
| Prognosis | 2 | 2004 | 29052 | 0.010 |
Why?
|
| Binding Sites | 2 | 2004 | 6111 | 0.010 |
Why?
|
| Urine | 1 | 2005 | 370 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 1862 | 0.010 |
Why?
|
| Electrons | 1 | 2005 | 268 | 0.010 |
Why?
|
| Heart | 2 | 2010 | 4460 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2009 | 2617 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 644 | 0.010 |
Why?
|
| Drug Discovery | 1 | 2011 | 1058 | 0.010 |
Why?
|
| Age Factors | 2 | 2014 | 18355 | 0.010 |
Why?
|
| Necrosis | 1 | 2007 | 1642 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 2004 | 448 | 0.010 |
Why?
|
| Serpins | 1 | 2004 | 247 | 0.010 |
Why?
|
| Kinetics | 3 | 2004 | 6476 | 0.010 |
Why?
|
| Tattooing | 1 | 2003 | 58 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 489 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 420 | 0.010 |
Why?
|
| Genes, fms | 1 | 2002 | 6 | 0.010 |
Why?
|
| Lysosomes | 1 | 2007 | 893 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 689 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 504 | 0.010 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2002 | 89 | 0.010 |
Why?
|
| Immunologic Capping | 1 | 1981 | 31 | 0.010 |
Why?
|
| Mentors | 1 | 2007 | 631 | 0.010 |
Why?
|
| Deuterium Oxide | 1 | 1981 | 34 | 0.010 |
Why?
|
| Biological Transport | 1 | 1986 | 2119 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2002 | 300 | 0.010 |
Why?
|
| Young Adult | 3 | 2014 | 56392 | 0.010 |
Why?
|
| Deuterium | 1 | 1981 | 101 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2003 | 497 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 709 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2000 | 104 | 0.010 |
Why?
|
| Syndrome | 1 | 2007 | 3249 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 853 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2014 | 3207 | 0.010 |
Why?
|
| Axons | 1 | 1989 | 1685 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1985 | 1472 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 2000 | 173 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2009 | 1928 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2001 | 25609 | 0.010 |
Why?
|
| Atmospheric Pressure | 1 | 1980 | 47 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 1581 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 2034 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 1385 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 2050 | 0.010 |
Why?
|
| Response Elements | 1 | 2002 | 312 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 3772 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2002 | 768 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2002 | 513 | 0.010 |
Why?
|
| X-Rays | 1 | 1981 | 301 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 2009 | 39001 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 534 | 0.010 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2004 | 584 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1989 | 2107 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2000 | 173 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2001 | 25032 | 0.010 |
Why?
|
| Calcineurin | 1 | 2000 | 226 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 1536 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2298 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2009 | 53250 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1999 | 222 | 0.010 |
Why?
|
| Endotoxins | 1 | 2002 | 527 | 0.010 |
Why?
|
| Cell Proliferation | 2 | 2005 | 10477 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2000 | 379 | 0.010 |
Why?
|
| K562 Cells | 1 | 2001 | 635 | 0.010 |
Why?
|
| Lac Operon | 1 | 1999 | 239 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 915 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2899 | 0.010 |
Why?
|
| Infant | 1 | 2001 | 35122 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1999 | 192 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 2226 | 0.010 |
Why?
|
| Treatment Outcome | 4 | 2006 | 63042 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1999 | 347 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2003 | 924 | 0.010 |
Why?
|
| Desmosomes | 1 | 1998 | 73 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2014 | 7729 | 0.010 |
Why?
|
| Mesothelioma | 1 | 2005 | 818 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 601 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2014 | 23327 | 0.010 |
Why?
|
| Posture | 1 | 2003 | 957 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 1224 | 0.010 |
Why?
|
| Risk Factors | 3 | 2014 | 72252 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1998 | 112 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5170 | 0.010 |
Why?
|
| Liver | 2 | 2005 | 7479 | 0.010 |
Why?
|
| Survival Rate | 2 | 2002 | 12786 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 2016 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2566 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2000 | 788 | 0.010 |
Why?
|
| United States | 2 | 2007 | 69859 | 0.010 |
Why?
|
| Epitopes | 1 | 2004 | 2570 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 1899 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 1524 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2000 | 743 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 7010 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 3281 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 3847 | 0.010 |
Why?
|
| Heparin | 1 | 2004 | 1637 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 1678 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1996 | 263 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1997 | 337 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 2378 | 0.010 |
Why?
|
| Phosphoserine | 1 | 1996 | 206 | 0.010 |
Why?
|
| Prostate | 1 | 2005 | 1763 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 12798 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3917 | 0.010 |
Why?
|
| Tight Junctions | 1 | 1998 | 311 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 2266 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 1213 | 0.010 |
Why?
|
| Incidence | 2 | 2005 | 20948 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 10940 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1999 | 1159 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 2890 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 3574 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 3175 | 0.010 |
Why?
|
| Mortality | 1 | 2005 | 2862 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1985 | 2899 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1993 | 156 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 1993 | 178 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2002 | 2132 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 4406 | 0.010 |
Why?
|
| RNA | 1 | 2002 | 2748 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 1602 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 3482 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10251 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 4670 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 3128 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6237 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2002 | 3024 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 10380 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 9677 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 17439 | 0.010 |
Why?
|
| Aminoquinolines | 1 | 1988 | 109 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 2000 | 4152 | 0.000 |
Why?
|
| 3-O-Methylglucose | 1 | 1986 | 37 | 0.000 |
Why?
|
| Methylglucosides | 1 | 1986 | 36 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1988 | 462 | 0.000 |
Why?
|
| Rubidium | 1 | 1986 | 133 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 15526 | 0.000 |
Why?
|
| Surface-Active Agents | 1 | 1986 | 159 | 0.000 |
Why?
|
| Inositol | 1 | 1987 | 218 | 0.000 |
Why?
|
| Membrane Lipids | 1 | 1987 | 251 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7793 | 0.000 |
Why?
|
| Bucladesine | 1 | 1985 | 121 | 0.000 |
Why?
|
| Deoxyglucose | 1 | 1985 | 337 | 0.000 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2000 | 5532 | 0.000 |
Why?
|
| Dextran Sulfate | 1 | 1984 | 236 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1985 | 1386 | 0.000 |
Why?
|
| Adenosine Monophosphate | 1 | 1985 | 275 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2005 | 40545 | 0.000 |
Why?
|
| Membrane Fluidity | 1 | 1980 | 73 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1985 | 1606 | 0.000 |
Why?
|